Boston, MA – On January 24, 2018, Human Metabolome Technologies, Inc. (hereinafter referred to as HMT, Head office: Tsuruoka City, Yamagata Prefecture, President: Ryuji Kanno,) have announced that a biomarker for the diagnosis of Major Depression Disorder (MDD), which is being developed collaboratively with the Medical Corporation Association Gyo-ki kai, Kawamura general clinic (Tokyo, Japan, Representative: Noriyuki Kawamura, MD), has been published in Psychiatry and Clinical Neurosciences.
Published in Psychiatry and Clinical Neurosciences
The First diagnostic plasma metabolite biomarker for Major Depression Disorder (MDD) has been published in Psychiatry and Clinical Neurosciences.